Are the perspectives regarding the use of biosimilars in the setting of haematology and blood and marrow transplant changing?

Abstract

Introduction: Canada is among the leading spenders in pharmaceuticals. Based on projected figures, the cost of pharmaceuticals is expected to rise by another 6-12% by 2023. Approximately CAN$4.6 billion of healthcare funding is spent on biological drugs (including growth factors and monoclonal antibodies) which are commonly used in the setting of haematology and blood and marrow transplant. Aim: As healthcare funds become more scarce, a need to investigate cost-effective alternatives at both the federal and provincial levels to provide cancer care is imperative. Discussion: Biosimilars, also known as 'subsequent entry biologics' (SEB), are cheaper alternatives to biological drugs. Biosimilars have been utilized in many European countries for years with significant cost savings and no significant reporting of adverse events. In Canada, there is a reluctance to use biosimilars due to the potential risk of adverse effects which can occur if the biosimilar is interchanged with the originator product. In keeping with this reasoning, Alberta's stance is against substitutability or interchangeability of biosimilars/SEBs with the reference product. Conclusion: For the benefit of cost-effective, quality cancer care, it is time to re-examine the use of biosimilars in our province and understand if the potential risks outweigh the benefit of cost savings.